Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial

BACKGROUND: Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical and correlative data in humans suggest that anti-androgenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nickols, Nicholas G., Goetz, Matthew B., Graber, Christopher J., Bhattacharya, Debika, Soo Hoo, Guy, Might, Matthew, Goldstein, David B., Wang, Xinchen, Ramoni, Rachel, Myrie, Kenute, Tran, Samantha, Ghayouri, Leila, Tsai, Sonny, Geelhoed, Michelle, Makarov, Danil, Becker, Daniel J., Tsay, Jun-Chieh, Diamond, Melissa, George, Asha, Al-Ajam, Mohammad, Belligund, Pooja, Montgomery, R. Bruce, Mostaghel, Elahe A., Sulpizio, Carlie, Mi, Zhibao, Dematt, Ellen, Tadalan, Joseph, Norman, Leslie E., Briones, Daniel, Clise, Christina E., Taylor, Zachary W., Huminik, Jeffrey R., Biswas, Kousick, Rettig, Matthew B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256647/
https://www.ncbi.nlm.nih.gov/pubmed/34225789
http://dx.doi.org/10.1186/s13063-021-05389-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256647/
https://www.ncbi.nlm.nih.gov/pubmed/34225789
http://dx.doi.org/10.1186/s13063-021-05389-0

Ejemplares similares